Abstract: Provided is a process for the preparation of certain bisphosphonate compounds and their ester derivatives. In this process certain bisphosphonate compounds such as medronic acid is prepared via the reaction of the corresponding isopropyl esters with (i) trimethylsilylbromide or trimethylsilyl iodide, or (ii) trimethylsilyl chloride and an alkali metal iodide or bromide; followed by treatment with a liquid comprising water. The process surprisingly provides the desired compounds, despite having relatively bulky ester groups such as isopropyl on the starting material bisphosphonate ester.

Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

Abstract: Embodiments provide an organometallic compound, a light-emitting device including the organometallic compound, and an electronic apparatus and an electronic equipment that include the light-emitting device.

Abstract: It is provided a process for producing lactosucrose from a source of lactose such as whey permeate and a source of sucrose as well as a source of both lactose/sucrose such as chocolate milk to enzymatically generating in situ lactosucrose, and fructosylate phenolic compounds contained therein, the process comprising contacting the dairy starting material (containing sucrose) with a levansucrase (LS), which can be immobilized on a solid support, selected from Bacillus amyloliquefaciens (ATCC 23350), Gluconobacter oxydans (strain 621H) (LS1), Vibrio natriegens NBRC 15636 (LS2), Novosphingobium aromaticivorans (LS3), and Burkholderia graminis C4D1M (LS4), or a combination thereof.

Abstract: The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

Abstract: The present invention provides a benzimidazole derivative represented by the following Chemical Formula 1, a preparation method thereof, and use thereof as an anticancer or anti-virus agent: wherein, R1, R2, R3 and X are as defined in the detailed description and the claims.

Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.

Abstract: Oxidizing an oligonucleotide precursor having a phosphite ester bond or a phosphonate ester bond with an oxidant, wherein the oxidant is a compound represented by the formula (I) excluding 2,2-dipyridyl disulfide: wherein the symbols are as defined in the specification is useful for producing an oligonucleotide having a phosphate ester bond.

Abstract: The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroid used for the treatment of acne.

Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.

Abstract: Provided herein are novel solutions for the identification and measurement of protective proteins to treat and prevent honey bee infections.

Abstract: The present invention concerns a method of cleaning and/or sanitizing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of: a) optionally purifying a mixture comprising a first immunoglobulin using the separation matrix; b) providing a cleaning liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; and c) cleaning and/or sanitizing the separation matrix by contacting the cleaning liquid with the separation matrix for a predetermined contact time.

Abstract: A method for estimating a purified state includes quantifying a component that is included in a treatment liquid obtained by performing a purification treatment on a liquid including a specific protein and impurities other than the protein. The method for estimating a purified state includes acquiring an estimated value of a concentration of the impurities on the basis of spectral data indicating an intensity of electromagnetic waves, which have been emitted to the treatment liquid and have been subjected to an action of the treatment liquid, for each wave number or wavelength. The concentration of the impurities included in the treatment liquid is equal to or less than 20 mg/mL, and a weight ratio of the impurities to a mixture including the protein and the impurities is equal to or less than 15%.

Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Abstract: Provided herein are polypeptides that include one or more ?-tricalcium phosphate (?TCP)-binding sequence(s) and uses thereof.

Abstract: The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair and cell death.

Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.

Abstract: In various embodiments, a synthetic peptide finding use as a molecular wire in a molecular electronic circuit comprises an alpha helical segment further comprising repeating alpha-helical motifs. The synthetic peptide may further comprise at least one specific conjugation site between the termini for attachment to a molecule such as a binding probe, and may further comprise termini having metal binding functionality such as repeats of material binding sequences. In various aspects, the synthetic peptide comprises intramolecular hydrogen bonding, salt bridges, and optionally, aromatic rings that provide for electrical conductivity through the peptide.

Abstract: This invention relates to chimeric coronavirus S proteins and methods of their use, for example, to treat and/or prevent diseases or disorders caused by infection by a coronavirus.

Abstract: The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs. Methods of using the lysin-AMP polypeptide constructs, isolated lysin polypeptides and pharmaceutical compositions are also herein provided. In addition, isolated polynucleotides encoding the lysin-AMP polypeptide constructs and isolated lysin polypeptides are disclosed herein.

Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.

Abstract: Provided herein are chimeric polypeptides that may be used, e.g., for the diagnosis of or vaccination against Ehrlichia chaffeensis and/or Ehrlichia canis.

Abstract: The present disclosure provides chimeric polypeptides that include one or more zinc finger motif fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It is shown that the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally.

Abstract: A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.

Abstract: New insecticidal peptides, polypeptides, proteins, and nucleotides; their expression in culture and plants; methods of producing the peptides, polypeptides, proteins, and nucleotides; new processes; new production techniques; new formulations; and new organisms, are disclosed. The present disclosure is also related to a novel type of peptide named Dc1a-Variant Polypeptides (DVPs) that are a non-naturally occurring, modified-form of the peptide, Mu-diguetoxin-Dc1a, isolated from the American Desert Spider (Diguetia canities). Here we describe: genes encoding DVPs; various formulations and combinations of both genes and peptides; and methods for using the same that are useful for the control of insects. Further, the present invention relates to novel, recombinant cysteine rich proteins (CRPs) with a cystine knot (CK) architecture, created by removing one or more disulfide bonds from a polypeptide having four or more disulfide bonds.

Abstract: Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.

Abstract: The present disclosure relates to compositions, vectors, constructs, cells and methods for the reprogramming of cells into natural killer (NK) cells or progenitors. In particular, it relates to a combination of transcription factors for the reprogramming of cells.

Abstract: Provided are multivalent binding proteins comprising four polypeptide chains, wherein a first heavy chain polypeptide and a first light chain polypeptide associate to form one or more antigen binding domains and a second heavy chain polypeptide and a second light chain polypeptide associate to bind one or more antigen binding domains. Also provided are methods of purifying such multivalent binding proteins.

Abstract: Disclosed herein are fusion proteins comprising the CR3 domain of the low density lipoprotein (LDLR) and a polypeptide with phase behavior. Also provided herein are polypeptides with phase behavior. Additionally provided herein are methods of improving or decreasing viral transduction efficiency comprising administering a fusion protein or polypeptide with phase behavior described herein.

Abstract: The present disclosure provides zinc finger fusion proteins that inhibit expression of alpha-synuclein in the nervous system, and methods of using the proteins to treat Parkinsons disease, Lewy body dementia, multiple system atrophy, Alzheimers disease, and other neurodegenerative diseases.

Abstract: A fusion molecule having phagocytosis-inducing activity, without can avoid or reduce a tissue damage caused by activation of an inflammatory reaction is disclosed. The fusion molecule contains a first region capable of binding a TAM receptor and a second region capable of binding to a target substance of which aberrant accumulation is associated with or characteristic of diseases. The fusion molecule effectively clears and/or reduces and/or suppresses accumulated abnormal proteins, such as beta-amyloid, tau, alpha-synuclein, huntingtin, or prion, or the like. Uses of the fusion molecule are disclosed. The fusion molecules can be used for prevention or treatment of proteinosis caused by the abnormal accumulation of substances.

Abstract: The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

Abstract: Provided is an Interleukin-1 Receptor Antagonist (IL-1RN) protein or a variant or analogue thereof, and a fusion protein comprising the following three-parts: the Interleukin-1 Receptor Antagonist protein or a variant or analogue thereof, a domain for half-life extension and an optional tumor necrosis factor receptor 2, and the preparation method and use thereof. The above-mentioned protein mutant and fusion protein have the effects of extended half-life, improved affinity with interleukin-1 receptor and superior biological activity, and find use in the field of treatment and prevention of inflammatory-associated diseases.

Abstract: The invention provides novel Fc-fusion proteins of interferon tau and compositions thereof, methods of their preparation and therapeutic use thereof in treating coronavirus (e.g., COVID-19 virus/SARS-CoV-2 and hCoV229E) viral infections, and related diseases and conditions.

Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

Abstract: A fusion protein including a glucagon-like peptide-1 (GLP-1) receptor agonist and an anti-osteoclast-associated receptor (OSCAR) antibody; a pharmaceutical composition for preventing or treating arthritis including the fusion protein; a food composition; a health functional food composition; and a method of preventing or treating arthritis, the method including administering the fusion protein. The fusion protein including a GLP-1 receptor agonist and an anti-OSCAR antibody has excellent effects on protecting cartilage and relieving pain and thus may be widely used for treatment of arthritis.

Abstract: Disclosed is a cell expressing a modified CD3 subunit chain or a cell expressing a modified non-CD3 subunit chain comprising one or more of: (a) at least one Immuno-receptor Tyrosine-based Activation Motif (ITAM) deletion; or (b) at least one exogenous intracellular hematopoietic cell signaling domain; and (c) at least one modified ITAM comprising an amino acid sequence of Formula I. Related populations of cells, pharmaceutical compositions, methods of making the cells, methods of treating or preventing a condition in a subject, and methods of enhancing an antigen-specific immune response in a subject are also disclosed.

Abstract: A method is provided for producing exosomes containing an overexpressed CD64 or a portion thereof. The method includes transducing a genetic construct encoding a full-length CD64 or a portion thereof into cells that do not naturally express CD64 or a portion thereof, without fusion with a nucleic acid sequence encoding an exogenous transmembrane protein or a transmembrane domain thereof; expressing the genetic construct in the cells; culturing the cells in a medium; and isolating exosomes secreted or released into the cell culture medium.

Abstract: Provided are a drug for treating Sjogren's syndrome using a TACI-Fc fusion protein, and a dosage regimen, a dosing interval and an administration mode thereof. The results show that the provided TACI-Fc fusion protein significantly improves the ESDAI score and the MF-20 score at 24 weeks in a patient with Sjogren's syndrome, and same exhibits good security during treatment.

Abstract: Described herein are Notch-modulating peptides (including monomers and multimers) capable of increasing or decreasing an immune response in a subject, compositions comprising the peptides, and methods of use thereof.

Abstract: In order to further increase antigenicity to provide a DNA vaccine which is clinically usable in humans, the inventors of the present invention focused on exosomes, which are garnering attention as tools for DDS, and discovered that an exosome expressing a fusion antigen of an exosome (extracellular microparticle)-constituent protein and a vaccine antigen has excellent cytotoxic T-cell inducibility. Consequently, the present invention provides a nucleic acid constituent including a nucleic acid sequence coding for an exosome marker protein and a nucleic acid sequence coding for a vaccine antigen.

Abstract: The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition. For example, disclosed herein are genetically-modified cells comprising a chimeric antigen receptor or an inducible regulatory construct incorporating the co-stimulatory domains disclosed herein. Also disclosed herein are plasmids and viral vectors comprising a nucleic acid sequence encoding the co-stimulatory domains, and methods of administering compositions comprising the novel co-stimulatory domains to subjects in order to reduce the symptoms, progression, or occurrence of disease, such as cancer.

Abstract: The current application describes various compositions and methods for the production of FN3-based binding proteins with improved stability properties. Aspects of the disclosure relate to polypeptides comprising a variant fibronectin type III (FN3) domain from Sulfolobus tokodaii or Pyrococcus horikoshii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.

Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind a SARS-CoV-2 antigen and are in certain embodiments capable of neutralizing a SARS-CoV-2 infection. Polynucleotides encoding an antibody or an antigen-binding fragment, vectors and host cells that comprise a polynucleotide and pharmaceutical compositions are also included in this invention. Also described herein are methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to diagnose, prevent or treat a SARS-CoV-2 infection.

Abstract: An antiviral composition includes an antibody or a fragment thereof, which includes a heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1, VH CDR2 represented by SEQ ID NO: 2, VH CDR3 represented by SEQ ID NO: 3, a light chain CDR1 (VL CDR1) represented by SEQ ID NO: 4, VL CDR2 represented by SEQ ID NO: 5, and VL CDR3 represented by SEQ ID NO: 6, so as to exhibit excellent antiviral effects to influenza A virus, while achieving effects of preventing, treating or improving diseases derived from influenza A virus.

Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding the anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.

Abstract: Provided herein are methods of treatment designed to prevent or minimize formation of deleterious multivalent immune complexes in a human patient having a complement mediated disorder (e.g., paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS)), who has been or is being treated with a first anti-C5 antibody and is then treated with a second (different) anti-C5 antibody, as well as methods of safely switching a patient from treatment with a first anti-C5 antibody to a second (different) anti-C5 antibody. Also provided are methods for determining an adjusted regimen antibody (e.g., a regimen to prevent or minimize formation of multivalent immune complexes) comprising an adjusted therapeutic dose and/or timing of administration of a second anti-C5 to treat a patient who has been or is being treated with a first anti-C5 antibody.

Abstract: The invention relates generally to antigen-binding molecules that specifically bind to Myosin Heavy Chain 9 (MYH9) and uses thereof for the treatment of specific cancers, such as mast cell tumors. In one embodiment, the MYH9 is canine MYH9 and the antigen-binding molecule is an antibody. In another embodiment, the antigen-binding molecule is conjugated to a toxin, for the treatment of canine mast cell tumors.

Abstract: A monoclonal antibody inhibiting an SMIM15 and application thereof; the antibody is secreted by a hybridoma cell strain 1M5. A preparation method includes: preparing mouse immunogen and an antigen for detection; preparing the hybridoma cell strain 1M5 against an SMIM15; screening an SMIM15 positive monoclonal antibody: identifying a subtype of the monoclonal antibody; detecting specificity of the SMIM15 positive monoclonal antibody; producing and purifying the monoclonal antibody in a BALB/c mouse; detecting purity of the antibody by SDS-PAGE; and performing function identification and application on the SMIM15 monoclonal antibody with WB, IHC and ELISA. According to the present application, the antibody secreted by the hybridoma cell strain 1M5 is an immunoglobulin, which is non-toxic, and can be used for Western blot and immunohistochemistry and used as an active ingredient to be made into a reagent or drug for diagnosis and treatment of SMIM15-related diseases.